Yoo Taeyeon, Bae Sun Hwan
Department of Pediatrics, Konkuk University school of Medicine, Seoul, Korea.
Pediatr Gastroenterol Hepatol Nutr. 2017 Dec;20(4):244-251. doi: 10.5223/pghn.2017.20.4.244. Epub 2017 Dec 22.
We evaluated the efficacy and safety of combined oral and enema therapy using polyethylene glycol (PEG) 3350 with electrolyte solution for disimpaction in hospitalized children.
We retrospectively studied 28 children having functional constipation who received inpatient treatment between 2008 and 2016. The amount of oral PEG 3350 electrolyte solution administered was 50-70 mL/kg/d (PEG 3350, 3-4.1 g/kg/d), and an enema solution was administered 1-2 times a day as a single dose of 15-25 mL/kg (PEG 3350, 0.975-1.625 g/kg/d). A colon transit time (CTT) test based on the Metcalf protocol was performed in some patients.
Administration of oral and enema doses of PEG 3350 electrolyte solution showed 2.1±0.3 times and 2.9±0.4 times, respectively. After disimpaction, the frequency of defecation increased from 2.2±0.3 per week to once a day (1.1±0.1 per day). The number of patients who complained of abdominal pain was reduced from 15 (53.6%) to 4 (14.3%). Before hospitalization, nine patients underwent a CTT test, and 5 of 9 patients (55.6%) were classified as belonging to a group showing abnormalities. And in some patients, mild adverse effects were noted. We examined electrolytes and osmolality before and after disimpaction in 16 of 28 patients, and no abnormalities were noted.
In terms of therapeutic efficacy and safety, combined oral and enema therapy using high-dose PEG 3350 with electrolytes is considered superior to conventional oral monotherapy or combined oral and enema therapy on an outpatient basis.
我们评估了使用聚乙二醇(PEG)3350与电解质溶液联合口服和灌肠疗法对住院儿童进行粪便嵌塞治疗的疗效和安全性。
我们回顾性研究了2008年至2016年间接受住院治疗的28例功能性便秘儿童。口服PEG 3350电解质溶液的剂量为50 - 70 mL/kg/d(PEG 3350,3 - 4.1 g/kg/d),灌肠溶液每天给药1 - 2次,单次剂量为15 - 25 mL/kg(PEG 3350,0.975 - 1.625 g/kg/d)。部分患者基于梅特卡夫方案进行了结肠运输时间(CTT)测试。
口服和灌肠剂量的PEG 3350电解质溶液给药次数分别显示为2.1±0.3次和2.9±0.4次。粪便嵌塞解除后,排便频率从每周2.2±0.3次增加到每天一次(每天1.1±0.1次)。主诉腹痛的患者数量从15例(53.6%)减少到4例(14.3%)。住院前,9例患者进行了CTT测试,9例患者中有5例(55.6%)被归类为异常组。并且在一些患者中,观察到了轻微的不良反应。我们对28例患者中的16例在粪便嵌塞解除前后检查了电解质和渗透压,未发现异常。
在治疗效果和安全性方面,使用高剂量PEG 3350与电解质联合口服和灌肠疗法被认为优于传统口服单一疗法或门诊基础上的联合口服和灌肠疗法。